Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SANA · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including SANA · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SANA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -30.7% | -4.3% | 14% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -26.8% | -0.8% | 15% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -18.5% | -2.3% | 18% | 20% | |
| Book yieldHigher is better · 587 reported | 21.1% | 25.9% | 44% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 313 | 41.6B USD | 8 | 34 | |
| 313 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 2.0B USD |
| 8 |
| 24 |
| 313 | 6.0B USD | 8 | 32 |
| 313 | 388M USD | 8 | 36 |
| 313 | 730M USD | 8 | 11 |
| 313 | 2.0B USD | 8 | 26 |
| 313 | 468M USD | 8 | 40 |
| 313 | 2.0B USD | 8 | 53 |
| 313 | 519M USD | 8 | 22 |